In this regard, it is interesting to note that previous studies have demonstrated a significant benefit of PDGFRα antagonists in several CNS pathologies and injuries, including ischemic and hemorrhagic stroke [61, 71], spinal cord injury [2, 33], experimental autoimmune encephalomyelitis (a model for multiple sclerosis) [3], traumatic brain injury [63], and amyotrophic lateral sclerosis [40], all disorders where neuroinflammation is thought to play a role. The gene discussed is PDGFRA; the disease is multiple sclerosis.